Search

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with...

BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM.


https://www.nature.com/articles/s41416-021-01259-3.pdf


Source: British Journal of Cancer via nature.com

4 views

© 2021 36Eight Technologies Inc.     |     Privacy Policy     |     Terms of Use